ESAs Linked to Ovarian Cancer Mortality (Medpage)


A study presented at the Society for Gynecologic Oncology annual meeting in March, 2011 showed that women treated with ESAs had higher rates of ovarian cancer recurrence and death. ESAs (erythropoetin stimulating agents) are used to promote the growth of red blood cells, but have been found to have serious side effects.  Patients with ovarian cancer who have anemia should consult their doctors regarding treatment options.

See the full article here